Recombinant factor VIIa, its clinical properties, and the tissue factor pathway of coagulation.
Recombinant factor VIIa (rFVIIa) is a synthetic coagulation protease that is structurally similar to human-derived plasma FVIIa. Pharmacologic doses of rFVIIa have been shown to enhance thrombin generation and assist in forming stable fibrin plugs at the site of injury. Recombinant factor VIIa appears to emerge as a valuable treatment alter-native for the treatment of bleeding episodes and for achieving hemostasis post surgery in those with bleeding disorders.
Bosinski
Timothy J
TJ
Medical Affairs, Novo Nordisk Inc., Princeton, New Jersey, USA.
El Solh
Ali A
AA
D001777:Blood Coagulation / Q000187:drug effects*; D001779:Blood Coagulation Factors / Q000737:chemistry; D005167:Factor VII / Q000737:chemistry / Q000627:therapeutic use*; D005168:Factor VII Deficiency / Q000188:drug therapy*; D015942:Factor VIIa; D006801:Humans; D011994:Recombinant Proteins / Q000737:chemistry / Q000627:therapeutic use
D001779:Blood Coagulation Factors; D011994:Recombinant Proteins; D005167:Factor VII; C103587:recombinant FVIIa; D015942:Factor VIIa